← Back to Search

Gene Therapy

30 mg dose of JVS-100 for Heart Failure (RETRO-HF Trial)

Phase 1 & 2
Waitlist Available
Research Sponsored by Juventas Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
ASA unless contraindicated
Willing and able to sign informed consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 and/or 12 months
Awards & highlights

RETRO-HF Trial Summary

A phase I/II study to evaluate the safety and efficacy of JVS-100 administered by retrograde delivery to cohorts of adults with Ischemic Heart Failure.

Eligible Conditions
  • Heart Failure

RETRO-HF Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

RETRO-HF Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 and/or 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 and/or 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Impact of JVS-100 delivery on 6 minute walk distance at 4 month follow-up
Secondary outcome measures
Impact of JVS-100 delivery on heart failure symptoms compared to placebo at 4 and/or 12 month follow-up
Other outcome measures
Impact of JVS-100 delivery on quality of life measure at 4 month follow-up

RETRO-HF Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: 45 mg dose of JVS-100Experimental Treatment2 Interventions
Group II: 30 mg dose of JVS-100Experimental Treatment2 Interventions
Group III: PlaceboPlacebo Group2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670

Find a Location

Who is running the clinical trial?

Juventas Therapeutics, Inc.Lead Sponsor
5 Previous Clinical Trials
440 Total Patients Enrolled
3 Trials studying Heart Failure
272 Patients Enrolled for Heart Failure

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure
2013. "Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01961726.
All > Anterior Ischemic Optic Neuropathy
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top